JBC: Researchers decipher how barbiturates work
Modern medicine would be unthinkable without the use of anesthesia during surgical procedures. In a recent paper in the Journal of Biological Chemistry that was selected as one of the Editors’ Picks, Marc Delarue of the Pasteur Institute in France and colleagues solved how a class of drugs called barbiturates function to induce anesthesia. “This work describes, for the first time, the three-dimensional structure by X-ray crystallography of barbiturates bound to the target receptor,” says Zaineb Fourati, one of the first authors on the paper. She adds, “Understanding the mechanism underlying anesthetics’ action is the first step toward the conception of better ones that are more specific and with less side effects.”Researchers unveil barbiturates’ mechanism of action.IMAGE COURTESY OF MARC DELARUE
Barbiturates, a class of drugs derived from barbituric acid, made their debut in Germany in 1903. Their name is thought to be a fusion of “Barbara” and uric acid, a component of urine. Sources are divided on which female inspired the name, who could have been St. Barbara or someone less than a saint.
The first commercially available form of barbiturates was marketed as sleeping pills. Other medical applications of barbiturates soon emerged, including as anesthetics, sedatives and anticonvulsants, which led to their widespread use in the first half of the 20th century. However, the side effects of barbiturates led to their regulation and decreased popularity.
“Uncontrolled use of barbiturates could have hazardous consequences, from addiction to death by overdose,” says Fourati. “One concrete example is the presumably intentional death of the famous Marilyn Monroe due to a barbiturate overdose in the early 1960s.” Nevertheless, barbiturates remain essential in the treatment of epilepsy and as an intravenous general anesthetic.
Anesthetics act by decreasing the relay of information in the nervous system. Specifically, anesthetics affect several types of membrane-embedded ion channels. The principal targets of barbiturates are thought to be anionic and cationic pentameric ligand-gated ion channels, known as pLGICs. Although there is some evidence to show that barbiturates bind to the cylindrical pore of the ion channel, the exact nature of this interaction is unclear.
To understand this interaction better, Delarue and colleagues used the bacterial pH-gated receptor GLIC, which has high structural similarity to mammalian pLGICs. They first showed that the bacterial version of the channel behaved much like its eukaryotic counterpart by demonstrating that a specific barbiturate called pentobarbital can inhibit the electrical current of the bacterial GLIC channel.
Next, the investigators used three barbiturate derivatives — bromobarbital, thiopental and selenocyanobarbital — that were modified chemically such that they displayed an unusual electron scattering behavior to help assign bound ligands in the X-ray structure unambiguously. The investigators showed that all three barbiturate derivatives bound to the closed GLIC channel deep within the central pore, and they used computational simulations of the channel in open and desensitized states to support their findings further.
“This work partly reveals how barbiturates induce anesthesia,” says Fourati. “As these drugs act on the nervous system, it is very important to address the exact mechanism of their action, and the structure provides a direct proof of a molecule binding to a given site.”
She and her colleagues think that the knowledge gained in this study can help design a new generation of barbiturates not only for anesthesia but also for psychiatric and neurological disorders.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Using multiplexed inhibitor beads and mass spectrometry, a team at Fox Chase Cancer Center writes in MCP that they have identified a network of kinases that are overexpressed, including SRPK1.
Solving this problem with DeepMInd could have profound implications for creating new drugs and understanding diseases as disparate as Alzheimer’s and cystic fibrosis.
Maria Podbielska and colleagues at the Hirszfeld Institute write in the Journal of Lipid Research about their finding that ceramide levels vary in active and inactive MS lesions in the nervous system.
Simulations on the nation’s fastest supercomputer confirm details of a molecular mechanism that cell organelles use to regulate the pH of their environment.